Tyra Biosciences Inc (TYRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tyra Biosciences Inc (TYRA) has a cash flow conversion efficiency ratio of -0.091x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.62 Million) by net assets ($259.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TYRA net asset quality score to measure how much of total assets are equity-financed.
Tyra Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Tyra Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Tyra Biosciences Inc (TYRA) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Tyra Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tyra Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Success Electronics Ltd
SHE:002289
|
0.049x |
|
Westshore Terminals Investment Corp
TO:WTE
|
0.127x |
|
Lotte Chemical Corp
KO:011170
|
-0.034x |
|
Hyundai Doosan Infracore Co Ltd
KO:042670
|
0.072x |
|
Greatoo Inc
SHE:002031
|
-0.100x |
|
Shandong Pharmaceutical Glass Co Ltd
SHG:600529
|
0.005x |
|
Qingdao Baheal Medical INC.
SHE:301015
|
0.079x |
|
Nexa Resources SA
NYSE:NEXA
|
0.238x |
Annual Cash Flow Conversion Efficiency for Tyra Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tyra Biosciences Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Tyra Biosciences Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $259.18 Million | $-95.14 Million | -0.367x | -80.54% |
| 2024-12-31 | $343.15 Million | $-69.77 Million | -0.203x | +17.16% |
| 2023-12-31 | $204.26 Million | $-50.14 Million | -0.245x | -25.86% |
| 2022-12-31 | $257.83 Million | $-50.28 Million | -0.195x | -147.84% |
| 2021-12-31 | $301.74 Million | $-23.75 Million | -0.079x | -113.82% |
| 2020-12-31 | $-13.64 Million | $-7.76 Million | 0.569x | +3.08% |
| 2019-12-31 | $-4.74 Million | $-2.62 Million | 0.552x | -- |
About Tyra Biosciences Inc
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. It… Read more